Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | TSPO | P30536 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10181786 | 0.87 | NPC1 (0.58) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL23252470 | 0.87 | NPC1 (0.58) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL21872480 | 0.86 | NPC1 (0.56) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL5205176 | 0.85 | NPC1 (0.60) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL4022321 | 0.85 | MAPT (0.71) | NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL4022324 | 0.85 | MAPT (0.71) | NPC1RAB9AMAPTALDH1A1 | |
| Dibemethine SCHEMBL9416516 | 0.85 | NPC1 (0.63) | NPC1RAB9ACA12CA9KMT2A | |
| Dibemethine SCHEMBL9416520 | 0.85 | NPC1 (0.63) | NPC1RAB9ACA12CA9KMT2A | |
| SCHEMBL12172749 | 0.85 | MAPT (0.71) | NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL21226256 | 0.84 | NPC1 (0.54) | NPC1RAB9ACA12CA9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912831-B2 | Hydroxyethylpyrrolidone ethacrylate/glycidyl ethacrylate copolymers | ISP INVESTMENTS LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-7482379-B2 | Propenoyl hydrazides | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| US-20050256058-A1 | Propenoyl hydrazides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912831-B2 | Hydroxyethylpyrrolidone ethacrylate/glycidyl ethacrylate copolymers | MMAB, PCNA, HMBS | NPC1 4879/4885RAB9A 3875/4885CA12 1204/4885 |
| US-20050256058-A1 | Propenoyl hydrazides | DNPEP, HPN, PREP | NPC1 2408/4885RAB9A 1761/4885CA12 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.